Subsequently, numerous studies have reported that ANRIL is independently associated with several other forms of cancer at the genome-wide level and is upregulated in many cancers including colorectal cancer [19], nasopharyngeal carcinoma [20], gallbladder cancer [21], hepatocellular carcinoma [22], non-small cell lung cancer [23], cervical cancer [24], gastric cancer [25], serous ovarian cancer [26], and thyroid cancer [27]. This evidence concerns the gene CDKN2B-AS1 and thyroid cancer.